Lixte Biotechnology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 4
- Market Cap
- -
- Website
- http://www.lixte.com
- Introduction
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also involved in utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on May 24, 2005 and is headquartered in Pasadena, CA.
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Lixte Biotechnology Holdings, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT03886662
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Phase I Study of LB-100 With Docetaxel in Solid Tumors
- Conditions
- NeoplasmsTumorsCancer
- Interventions
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Lixte Biotechnology Holdings, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01837667
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
News
Lixte Biotechnology Amends Collaboration Agreement for LB-100 Cancer Drug Development
Lixte Biotechnology Holdings amended its collaboration with the Netherlands Cancer Institute and Oncode Institute, focusing on LB-100 in cancer treatment.
Lixte Biotechnology Receives Nasdaq Extension and Advances LB-100 Clinical Trial
Lixte Biotechnology secured a Nasdaq extension until February 18, 2025, to meet the minimum stockholders' equity requirement of $2.5 million.
Lixte Biotechnology Faces Nasdaq Delisting Over Equity Shortfall, Plans Compliance Measures
Lixte Biotechnology received a Nasdaq notice for failing to meet the minimum stockholders' equity requirement of $2.5 million.
Paradoxical Intervention: A Novel Strategy to Overload Cancer Cells
Researchers are initiating a clinical trial using a 'paradoxical intervention' strategy to treat advanced colorectal cancer by overstimulating oncogenic signaling.
Lixte Biotechnology and Netherlands Cancer Institute Partner to Trial LB-100 in Metastatic Colon Cancer
Lixte Biotechnology partners with the Netherlands Cancer Institute to evaluate LB-100 in metastatic colon cancer patients.
Lixte Biotechnology's LB-100 Shows Promise in Multiple Cancer Indications Through Novel PP2A Inhibition
Lixte Biotechnology is advancing LB-100, a first-in-class protein phosphatase 2A (PP2A) inhibitor, for multiple cancer indications including soft tissue sarcoma and glioblastoma multiforme.